Marksans Pharma gets inspection report for New York unit
Marksans Pharma on Tuesday said it has received an establishment inspection report (EIR) from the US health regulator for company's manufacturing fac11-02-2020
11-02-2020
Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached an investors presentation of Marksans Pharma Limited for Q3 and 9M FY20.11-02-2020
Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Enclosed herewith kindly find a News Release dated February 11, 2020 of the Company.11-02-2020
Marksans Pharma Ltd - 524404 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31St, 2019 And Limited Review Reports Thereon.
In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results for the quarter and nine months ended December 31st, 2019 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today i.e. February 11, 2020 along with Limited Review Reports thereon. The meeting commenced at 12:00 p.m. and concluded at 12:50 p.m. In this connection, we hereby certify that the Auditors have given their reports on the Unaudited Financial Results for the quarter and nine months ended 31st December, 2019 (both Standalone and Consolidated) with unmodified opinion.11-02-2020
Marksans Pharma Ltd - 524404 - Receipt Of Establishment Inspection Report (EIR) From The US FDA For Company'S Manufacturing Facility Located At Farmingdale, New York, USA
We are pleased to announce receipt of Establishment Inspection Report (EIR) from the US FDA in respect of inspection of Company's manufacturing facility Time-Cap Laboratories Inc. located at Farmingdale, New York, USA carried out from 5th December, 2019 to 18th December 2019.11-02-2020
Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Notice Of Board Meeting
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2020 ,inter alia, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter ended 31st December, 2019.29-01-2020
Marksans Pharma Ltd - 524404 - Intimation With Respect To Redemption Of Unlisted Preference Shares Of The Company
We wish to inform you that the Company has redeemed 200,000 7% Redeemable Cumulative Preference Shares of Rs. 100/- each face value (Preference Shares) partly at par, on 17th January, 2020.17-01-2020
Marksans Pharma Ltd - 524404 - Shareholding for the Period Ended December 31, 2019
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here14-01-2020
MARKSANS PHARMA LTD. - 524404 - Shareholding for the Period Ended December 31, 2019
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here14-01-2020
Marksans Pharma Ltd - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2019 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company. You are requested to note the above in your records.14-01-2020